Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells.

Heukers R, Mashayekhi V, Ramirez-Escudero M, de Haard H, Verrips TC, van Bergen En Henegouwen PMP, Oliveira S.

Antibodies (Basel). 2019 Apr 4;8(2). pii: E26. doi: 10.3390/antib8020026.

2.

Semaphorin4D Induces Inhibitory Synapse Formation by Rapid Stabilization of Presynaptic Boutons via MET Coactivation.

Frias CP, Liang J, Bresser T, Scheefhals L, van Kesteren M, van Dorland R, Hu HY, Bodzeta A, van Bergen En Henegouwen PMP, Hoogenraad CC, Wierenga CJ.

J Neurosci. 2019 May 29;39(22):4221-4237. doi: 10.1523/JNEUROSCI.0215-19.2019. Epub 2019 Mar 26.

PMID:
30914448
3.

Imaging of Tumor Spheroids, Dual-Isotope SPECT, and Autoradiographic Analysis to Assess the Tumor Uptake and Distribution of Different Nanobodies.

Beltrán Hernández I, Rompen R, Rossin R, Xenaki KT, Katrukha EA, Nicolay K, van Bergen En Henegouwen P, Grüll H, Oliveira S.

Mol Imaging Biol. 2019 Mar 11. doi: 10.1007/s11307-019-01320-x. [Epub ahead of print] Erratum in: Mol Imaging Biol. 2019 Apr 15;:.

PMID:
30859470
4.

The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers.

Zanetti-Domingues LC, Korovesis D, Needham SR, Tynan CJ, Sagawa S, Roberts SK, Kuzmanic A, Ortiz-Zapater E, Jain P, Roovers RC, Lajevardipour A, van Bergen En Henegouwen PMP, Santis G, Clayton AHA, Clarke DT, Gervasio FL, Shan Y, Shaw DE, Rolfe DJ, Parker PJ, Martin-Fernandez ML.

Nat Commun. 2018 Oct 18;9(1):4325. doi: 10.1038/s41467-018-06632-0.

5.

Adaptive Resistance to EGFR-Targeted Therapy by Calcium Signaling in NSCLC Cells.

Mulder C, Prust N, van Doorn S, Reinecke M, Kuster B, van Bergen En Henegouwen P, Lemeer S.

Mol Cancer Res. 2018 Nov;16(11):1773-1784. doi: 10.1158/1541-7786.MCR-18-0212. Epub 2018 Jul 2.

PMID:
29967110
6.

MAGE-A antigens as targets for cancer immunotherapy.

Schooten E, Di Maggio A, van Bergen En Henegouwen PMP, Kijanka MM.

Cancer Treat Rev. 2018 Jun;67:54-62. doi: 10.1016/j.ctrv.2018.04.009. Epub 2018 Apr 26. Review.

PMID:
29763778
7.

A small protein probe for correlated microscopy of endogenous proteins.

de Beer MA, Kuipers J, van Bergen En Henegouwen PMP, Giepmans BNG.

Histochem Cell Biol. 2018 Mar;149(3):261-268. doi: 10.1007/s00418-018-1632-6. Epub 2018 Jan 11.

8.

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.

Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Hernández-Pérez S, Merino N, Bonet J, Navarro R, Van Bergen En Henegouwen PMP, Lykkemark S, Mikkelsen K, Mølgaard K, Jabs F, Sanz L, Blanco FJ, Roda-Navarro P, Alvarez-Vallina L.

Oncoimmunology. 2017 Sep 27;7(1):e1377874. doi: 10.1080/2162402X.2017.1377874. eCollection 2017.

9.

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017.

10.

Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors.

Xenaki KT, Oliveira S, van Bergen En Henegouwen PMP.

Front Immunol. 2017 Oct 12;8:1287. doi: 10.3389/fimmu.2017.01287. eCollection 2017.

11.

A novel immuno-gold labeling protocol for nanobody-based detection of HER2 in breast cancer cells using immuno-electron microscopy.

Kijanka M, van Donselaar EG, Müller WH, Dorresteijn B, Popov-Čeleketić D, El Khattabi M, Verrips CT, van Bergen En Henegouwen PMP, Post JA.

J Struct Biol. 2017 Jul;199(1):1-11. doi: 10.1016/j.jsb.2017.05.008. Epub 2017 May 25.

12.

Class III antiarrhythmic drugs amiodarone and dronedarone impair KIR 2.1 backward trafficking.

Ji Y, Takanari H, Qile M, Nalos L, Houtman MJC, Romunde FL, Heukers R, van Bergen En Henegouwen PMP, Vos MA, van der Heyden MAG.

J Cell Mol Med. 2017 Oct;21(10):2514-2523. doi: 10.1111/jcmm.13172. Epub 2017 Apr 19.

13.

Correction: Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.

de Bruin RCG, Stam AGM, Vangone A, van Bergen En Henegouwen PMP, Verheul HMW, Sebestyén Z, Kuball J, Bonvin AMJJ, de Gruijl TD, van der Vliet HJ.

J Immunol. 2017 May 1;198(9):3759. doi: 10.4049/jimmunol.1700317. No abstract available.

14.

Probing cytoskeletal modulation of passive and active intracellular dynamics using nanobody-functionalized quantum dots.

Katrukha EA, Mikhaylova M, van Brakel HX, van Bergen En Henegouwen PM, Akhmanova A, Hoogenraad CC, Kapitein LC.

Nat Commun. 2017 Mar 21;8:14772. doi: 10.1038/ncomms14772.

15.

Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.

de Bruin RC, Stam AG, Vangone A, van Bergen En Henegouwen PM, Verheul HM, Sebestyén Z, Kuball J, Bonvin AM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2017 Jan 1;198(1):308-317. Epub 2016 Nov 28. Erratum in: J Immunol. 2017 May 1;198(9):3759.

16.

EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR.

Kaplan M, Narasimhan S, de Heus C, Mance D, van Doorn S, Houben K, Popov-Čeleketić D, Damman R, Katrukha EA, Jain P, Geerts WJC, Heck AJR, Folkers GE, Kapitein LC, Lemeer S, van Bergen En Henegouwen PMP, Baldus M.

Cell. 2016 Nov 17;167(5):1241-1251.e11. doi: 10.1016/j.cell.2016.10.038. Epub 2016 Nov 10.

17.

High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display.

Salema V, Mañas C, Cerdán L, Piñero-Lambea C, Marín E, Roovers RC, Van Bergen En Henegouwen PM, Fernández LÁ.

MAbs. 2016 Oct;8(7):1286-1301. Epub 2016 Jul 29.

18.

Time-gated FRET nanoassemblies for rapid and sensitive intra- and extracellular fluorescence imaging.

Afsari HS, Cardoso Dos Santos M, Lindén S, Chen T, Qiu X, van Bergen En Henegouwen PM, Jennings TL, Susumu K, Medintz IL, Hildebrandt N, Miller LW.

Sci Adv. 2016 Jun 10;2(6):e1600265. doi: 10.1126/sciadv.1600265. eCollection 2016 Jun.

19.

Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications.

de Bruin RCG, Lougheed SM, van der Kruk L, Stam AG, Hooijberg E, Roovers RC, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2016 Aug;169:128-138. doi: 10.1016/j.clim.2016.06.012. Epub 2016 Jun 30.

20.

Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features.

Lameris R, de Bruin RC, van Bergen En Henegouwen PM, Verheul HM, Zweegman S, de Gruijl TD, van der Vliet HJ.

Immunology. 2016 Sep;149(1):111-21. doi: 10.1111/imm.12635.

21.

EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.

van Driel PBAA, Boonstra MC, Slooter MD, Heukers R, Stammes MA, Snoeks TJA, de Bruijn HS, van Diest PJ, Vahrmeijer AL, van Bergen En Henegouwen PMP, van de Velde CJH, Löwik CWGM, Robinson DJ, Oliveira S.

J Control Release. 2016 May 10;229:93-105. doi: 10.1016/j.jconrel.2016.03.014. Epub 2016 Mar 15.

22.

Site-specific conjugation of single domain antibodies to liposomes enhances photosensitizer uptake and photodynamic therapy efficacy.

Broekgaarden M, van Vught R, Oliveira S, Roovers RC, van Bergen en Henegouwen PM, Pieters RJ, Van Gulik TM, Breukink E, Heger M.

Nanoscale. 2016 Mar 28;8(12):6490-4. doi: 10.1039/c6nr00014b.

PMID:
26954515
23.

Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization.

Kijanka MM, van Brussel AS, van der Wall E, Mali WP, van Diest PJ, van Bergen En Henegouwen PM, Oliveira S.

EJNMMI Res. 2016 Dec;6(1):14. doi: 10.1186/s13550-016-0166-y. Epub 2016 Feb 10.

24.

PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time.

Kooijmans SAA, Fliervoet LAL, van der Meel R, Fens MHAM, Heijnen HFG, van Bergen En Henegouwen PMP, Vader P, Schiffelers RM.

J Control Release. 2016 Feb 28;224:77-85. doi: 10.1016/j.jconrel.2016.01.009. Epub 2016 Jan 7.

PMID:
26773767
25.

Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer.

van Brussel AS, Adams A, Oliveira S, Dorresteijn B, El Khattabi M, Vermeulen JF, van der Wall E, Mali WP, Derksen PW, van Diest PJ, van Bergen En Henegouwen PM.

Mol Imaging Biol. 2016 Aug;18(4):535-44. doi: 10.1007/s11307-015-0909-6.

26.

Resolving bundled microtubules using anti-tubulin nanobodies.

Mikhaylova M, Cloin BM, Finan K, van den Berg R, Teeuw J, Kijanka MM, Sokolowski M, Katrukha EA, Maidorn M, Opazo F, Moutel S, Vantard M, Perez F, van Bergen en Henegouwen PM, Hoogenraad CC, Ewers H, Kapitein LC.

Nat Commun. 2015 Aug 11;6:7933. doi: 10.1038/ncomms8933.

27.

Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein.

Navis AC, van Lith SA, van Duijnhoven SM, de Pooter M, Yetkin-Arik B, Wesseling P, Hendriks WJ, Venselaar H, Timmer M, van Cleef P, van Bergen En Henegouwen P, Best MG, Wurdinger TD, Tops BB, Leenders WP.

Acta Neuropathol. 2015 Jul;130(1):131-44. doi: 10.1007/s00401-015-1420-5. Epub 2015 Apr 11.

28.

Nanobody-based cancer therapy of solid tumors.

Kijanka M, Dorresteijn B, Oliveira S, van Bergen en Henegouwen PM.

Nanomedicine (Lond). 2015 Jan;10(1):161-74. doi: 10.2217/nnm.14.178. Review.

29.

Membrane domain formation-a key factor for targeted intracellular drug delivery.

Popov-Čeleketić D, van Bergen En Henegouwen PM.

Front Physiol. 2014 Dec 2;5:462. doi: 10.3389/fphys.2014.00462. eCollection 2014. Review.

30.

Bispecific antibody platforms for cancer immunotherapy.

Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, van der Vliet HJ.

Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65. doi: 10.1016/j.critrevonc.2014.08.003. Epub 2014 Aug 20. Review.

PMID:
25195094
31.

Membrane rearrangements mediated by coronavirus nonstructural proteins 3 and 4.

Hagemeijer MC, Monastyrska I, Griffith J, van der Sluijs P, Voortman J, van Bergen en Henegouwen PM, Vonk AM, Rottier PJ, Reggiori F, de Haan CA.

Virology. 2014 Jun;458-459:125-35. doi: 10.1016/j.virol.2014.04.027. Epub 2014 May 13.

32.

Nanobody-photosensitizer conjugates for targeted photodynamic therapy.

Heukers R, van Bergen en Henegouwen PM, Oliveira S.

Nanomedicine. 2014 Oct;10(7):1441-51. doi: 10.1016/j.nano.2013.12.007. Epub 2014 Jan 3.

PMID:
24394212
33.

Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody.

van Driel PB, van der Vorst JR, Verbeek FP, Oliveira S, Snoeks TJ, Keereweer S, Chan B, Boonstra MC, Frangioni JV, van Bergen en Henegouwen PM, Vahrmeijer AL, Lowik CW.

Int J Cancer. 2014 Jun 1;134(11):2663-73. doi: 10.1002/ijc.28601. Epub 2013 Dec 12.

34.

Analysis of EGF receptor oligomerization by homo-FRET.

de Heus C, Kagie N, Heukers R, van Bergen en Henegouwen PM, Gerritsen HC.

Methods Cell Biol. 2013;117:305-21. doi: 10.1016/B978-0-12-408143-7.00016-5.

PMID:
24143984
35.

Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles.

Heukers R, Altintas I, Raghoenath S, De Zan E, Pepermans R, Roovers RC, Haselberg R, Hennink WE, Schiffelers RM, Kok RJ, van Bergen en Henegouwen PM.

Biomaterials. 2014 Jan;35(1):601-10. doi: 10.1016/j.biomaterials.2013.10.001. Epub 2013 Oct 16.

PMID:
24139763
36.

Nanobodies and nanocrystals: highly sensitive quantum dot-based homogeneous FRET immunoassay for serum-based EGFR detection.

Wegner KD, Lindén S, Jin Z, Jennings TL, el Khoulati R, van Bergen en Henegouwen PM, Hildebrandt N.

Small. 2014 Feb 26;10(4):734-40. doi: 10.1002/smll.201302383. Epub 2013 Oct 2.

PMID:
24115738
37.

Targeting tumors with nanobodies for cancer imaging and therapy.

Oliveira S, Heukers R, Sornkom J, Kok RJ, van Bergen En Henegouwen PM.

J Control Release. 2013 Dec 28;172(3):607-17. doi: 10.1016/j.jconrel.2013.08.298. Epub 2013 Sep 11. Review.

PMID:
24035975
38.

Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif.

Heukers R, Vermeulen JF, Fereidouni F, Bader AN, Voortman J, Roovers RC, Gerritsen HC, van Bergen En Henegouwen PM.

J Cell Sci. 2013 Nov 1;126(Pt 21):4900-12. doi: 10.1242/jcs.128611. Epub 2013 Aug 13.

39.

Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.

van der Meel R, Oliveira S, Altintas I, Heukers R, Pieters EH, van Bergen en Henegouwen PM, Storm G, Hennink WE, Kok RJ, Schiffelers RM.

Mol Pharm. 2013 Oct 7;10(10):3717-27. doi: 10.1021/mp400212v. Epub 2013 Aug 23.

PMID:
23889133
40.

Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.

van Brussel AS, Adams A, Vermeulen JF, Oliveira S, van der Wall E, Mali WP, van Diest PJ, van Bergen En Henegouwen PM.

Breast Cancer Res Treat. 2013 Jul;140(2):263-72. doi: 10.1007/s10549-013-2635-6. Epub 2013 Jul 17.

PMID:
23860929
41.

Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.

Schmitz KR, Bagchi A, Roovers RC, van Bergen en Henegouwen PM, Ferguson KM.

Structure. 2013 Jul 2;21(7):1214-24. doi: 10.1016/j.str.2013.05.008. Epub 2013 Jun 20.

42.

Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery.

Kijanka M, Warnders FJ, El Khattabi M, Lub-de Hooge M, van Dam GM, Ntziachristos V, de Vries L, Oliveira S, van Bergen En Henegouwen PM.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1718-29. doi: 10.1007/s00259-013-2471-2. Epub 2013 Jun 19.

PMID:
23778558
43.

Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.

Zaiss DM, van Loosdregt J, Gorlani A, Bekker CP, Gröne A, Sibilia M, van Bergen en Henegouwen PM, Roovers RC, Coffer PJ, Sijts AJ.

Immunity. 2013 Feb 21;38(2):275-84. doi: 10.1016/j.immuni.2012.09.023. Epub 2013 Jan 17.

44.

Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine.

Varkevisser R, Houtman MJ, Waasdorp M, Man JC, Heukers R, Takanari H, Tieland RG, van Bergen En Henegouwen PM, Vos MA, van der Heyden MA.

Pflugers Arch. 2013 Feb;465(2):247-59. doi: 10.1007/s00424-012-1189-5. Epub 2012 Nov 29.

PMID:
23192368
45.

Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.

Altintas I, Heukers R, van der Meel R, Lacombe M, Amidi M, van Bergen En Henegouwen PM, Hennink WE, Schiffelers RM, Kok RJ.

J Control Release. 2013 Jan 28;165(2):110-8. doi: 10.1016/j.jconrel.2012.11.007. Epub 2012 Nov 16.

PMID:
23159529
46.

Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.

van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen en Henegouwen PM, Shah K.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16642-7. doi: 10.1073/pnas.1202832109. Epub 2012 Sep 25.

47.

A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies.

Oliveira S, Cohen R, Walsum MS, van Dongen GA, Elias SG, van Diest PJ, Mali W, van Bergen En Henegouwen PM.

EJNMMI Res. 2012 Sep 25;2(1):50. doi: 10.1186/2191-219X-2-50.

48.

Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody.

Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, van Diest PJ, van Bergen en Henegouwen PM.

Mol Imaging. 2012 Feb;11(1):33-46.

PMID:
22418026
49.

Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.

van der Meel R, Oliveira S, Altintas I, Haselberg R, van der Veeken J, Roovers RC, van Bergen en Henegouwen PM, Storm G, Hennink WE, Schiffelers RM, Kok RJ.

J Control Release. 2012 Apr 30;159(2):281-9. doi: 10.1016/j.jconrel.2011.12.027. Epub 2011 Dec 29.

PMID:
22227023
50.

Enhancement of polymeric immunoglobulin receptor transcytosis by biparatopic VHH.

Emmerson CD, van der Vlist EJ, Braam MR, Vanlandschoot P, Merchiers P, de Haard HJ, Verrips CT, van Bergen en Henegouwen PM, Dolk E.

PLoS One. 2011;6(10):e26299. doi: 10.1371/journal.pone.0026299. Epub 2011 Oct 14.

Supplemental Content

Loading ...
Support Center